• Episode: 62 - AI/ML in Antibody Discovery and Engineering: Reality, Hope, Future, and Hype

  • Jun 11 2024
  • Duración: 1 h y 4 m
  • Podcast

Episode: 62 - AI/ML in Antibody Discovery and Engineering: Reality, Hope, Future, and Hype

  • Resumen

  • his special episode of The Chain features a panel of industry experts who discussed AI and ML in antibody discovery and engineering at this year’s PEGS Boston event. Peter Tessier, professor at the University of Michigan; Andrew Bradbury, CSO at Specifica; Andrew Waight, Senior Director of Machine Learning, Discovery Biologics & Protein Sciences at Merck Research Labs; Peyton Greenside, Co-Founder & CSO of BigHat Biosciences; and Paolo Marcatili, Director of Antibody Design at Novo Nordisk take on where AI/ML has the biggest impact, what the hype is in the use of AI/ML in antibody discovery, how new AI/ML methods are being benchmarked against traditional discovery methods, and what controls should be used in an AI/ML discovery or optimization campaign.

    Más Menos

Lo que los oyentes dicen sobre Episode: 62 - AI/ML in Antibody Discovery and Engineering: Reality, Hope, Future, and Hype

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.